These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 1414631)
1. Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. Chappell PB; Leckman JF; Riddle MA; Anderson GM; Listwack SJ; Ort SI; Hardin MT; Scahill LD; Cohen DJ Adv Neurol; 1992; 58():253-62. PubMed ID: 1414631 [No Abstract] [Full Text] [Related]
2. Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome. Sandyk R Int J Neurosci; 1987 Jul; 35(1-2):93-4. PubMed ID: 3476477 [No Abstract] [Full Text] [Related]
3. The effects of naloxone in Tourette's syndrome. Sandyk R Ann Neurol; 1985 Sep; 18(3):367-8. PubMed ID: 3863543 [No Abstract] [Full Text] [Related]
4. Naloxone in Gilles de la Tourette's syndrome. Gadoth N; Gordon CR; Streifler J Ann Neurol; 1987 Apr; 21(4):415. PubMed ID: 3472487 [No Abstract] [Full Text] [Related]
5. Behavioral effects of haloperidol in young Tourette syndrome patients. Bogomolny A; Erenberg G; Rothner AD Adv Neurol; 1982; 35():427-32. PubMed ID: 6959520 [No Abstract] [Full Text] [Related]
6. Naloxone effect in Tourette syndrome. Berecz JM; Dysken MW; Davis JM Neurology; 1979 Sep; 29(9 Pt 1):1316-7. PubMed ID: 289910 [No Abstract] [Full Text] [Related]
7. Interaction of biological and psychological factors in the natural history of Tourette syndrome: a paradigm for childhood neuropsychiatric disorders. Cohen DJ; Detlor J; Shaywitz BA; Leckman JF Adv Neurol; 1982; 35():31-40. PubMed ID: 6959506 [No Abstract] [Full Text] [Related]
8. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures. Stein DJ; Hollander E; DeCaria CM; Simeon D; Cohen L; Aronowitz B Biol Psychiatry; 1996 Sep; 40(6):508-13. PubMed ID: 8879471 [TBL] [Abstract][Full Text] [Related]
9. [MDMA (ecstasy): neuroendocrine and behavioral features]. Gerra G; Zaimovic A; Moi G; Laviola G; Macchia T Ann Ist Super Sanita; 2002; 38(3):271-7. PubMed ID: 12645178 [TBL] [Abstract][Full Text] [Related]
11. [Gilles de la Tourette syndrome]. van de Wetering BJ; Cohen AP; Minderaa RB; Roos RA; van Woerkom TC Ned Tijdschr Geneeskd; 1988 Jan; 132(1):21-5. PubMed ID: 2895428 [No Abstract] [Full Text] [Related]
12. Therapeutics of Tourette syndrome. New medication approaches. LeWitt PA Adv Neurol; 1992; 58():263-70. PubMed ID: 1414632 [No Abstract] [Full Text] [Related]
13. [The behavior-neuroendocrine effects on the development of social behaviors]. Jia R; Tai FD Sheng Li Ke Xue Jin Zhan; 2005 Oct; 36(4):375-8. PubMed ID: 16408785 [No Abstract] [Full Text] [Related]
14. The natural history of Tourette syndrome: a follow-up study. Erenberg G; Cruse RP; Rothner AD Ann Neurol; 1987 Sep; 22(3):383-5. PubMed ID: 3479043 [TBL] [Abstract][Full Text] [Related]
15. Effects of nitric oxide on neuroendocrine function and behavior. Nelson RJ; Kriegsfeld LJ; Dawson VL; Dawson TM Front Neuroendocrinol; 1997 Oct; 18(4):463-91. PubMed ID: 9344634 [TBL] [Abstract][Full Text] [Related]
16. Tourette syndrome: not just a tic disorder. Wang HS Chang Gung Med J; 2005 Aug; 28(8):527-9. PubMed ID: 16265842 [TBL] [Abstract][Full Text] [Related]
17. Behavioral treatments for Tourette syndrome and tic disorders: state of the art. Piacentini J; Chang S Adv Neurol; 2001; 85():319-31. PubMed ID: 11530440 [No Abstract] [Full Text] [Related]